Clinical Trial

Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction

Completed Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this research is to find out if an aggressive intervention to lose weight, will improve symptoms in patients with obesity-related cardiomyopathy, which is also known as the obese phenotype of heart failure with preserved ejection fraction (HFpEF).
Protocol Amendment History 2 changes
critical Trial status changed: Enrolling by Invitation → Completed 2026-08-15
critical Phase changed: Phase 2 -> Phase 4 2026-07-03
Trial Details
NCT Number NCT05371496
Lead Sponsor Mayo Clinic
Collaborators: United States Department of Defense
Conditions Cardiomyopathy, Heart Failure With Preserved Ejection Fraction (HFpEF), Obesity
Enrollment 81 participants
Start Date 2022-09-06
Primary Completion 2026-07-17 (estimated)
Study Completion 2026-07-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-14